Suppr超能文献

急性心力衰竭预后评估:预后模型和生物标志物的重要作用

Assessment of acute heart failure prognosis: the promising role of prognostic models and biomarkers.

作者信息

Kadoglou Nikolaos P E, Parissis John, Karavidas Apostolos, Kanonidis Ioannis, Trivella Marialena

机构信息

Medical School, University of Cyprus, 215/6 Old road Lefkosias-Lemesou, 2029, Aglantzia, Nicosia, Cyprus.

Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.

出版信息

Heart Fail Rev. 2022 Mar;27(2):655-663. doi: 10.1007/s10741-021-10122-9. Epub 2021 May 25.

Abstract

Numerous models and biomarkers have been proposed to estimate prognosis and improve decision-making in patients with acute heart failure (AHF). The present literature review provides a critical appraisal of externally validated prognostic models in AHF, combining clinical data and biomarkers. We perform a literature review of clinical studies, using the following terms: "acute heart failure," "acute decompensated heart failure," "prognostic models," "risk scores," "mortality," "death," "hospitalization," "admission," and "biomarkers." We searched MEDLINE and EMBASE databases from 1990 to 2020 for studies documenting prognostic models in AHF. External validation of each prognostic model to another AHF cohort, containing at least one biomarker, was prerequisites for study selection. Among 358 initially screened studies, 9 of them fulfilled all searching criteria. The majority of prognostic models were simplified, including a narrow number of variables (up to 10), with good performance regarding calibration and discrimination (c-statistics > 0.65). Unfortunately, the derived and validated cohorts showed a wide variety in patients' characteristics (e.g., cause of AHF and therapy). Moreover, the prognostic models used various time-points and a plethora of combinations of variables determining different cut-off values. Although the application of valid prognostic models in AHF population is quite promising, a precise methodological approach should be set for the derivation and validation of prognostic models in AHF with unified characteristics to establish an effective performance in clinical practice.

摘要

已经提出了许多模型和生物标志物来评估急性心力衰竭(AHF)患者的预后并改善决策。本综述对结合临床数据和生物标志物的AHF外部验证预后模型进行了批判性评估。我们使用以下术语对临床研究进行了文献综述:“急性心力衰竭”、“急性失代偿性心力衰竭”、“预后模型”、“风险评分”、“死亡率”、“死亡”、“住院”、“入院”和“生物标志物”。我们在1990年至2020年期间检索了MEDLINE和EMBASE数据库,以查找记录AHF预后模型的研究。将每个预后模型在另一个包含至少一种生物标志物的AHF队列中进行外部验证是研究选择的前提条件。在最初筛选的358项研究中,有9项符合所有检索标准。大多数预后模型都很简化,包括数量有限的变量(最多10个),在校准和区分方面表现良好(c统计量>0.65)。不幸的是,推导队列和验证队列在患者特征(如AHF病因和治疗)方面存在很大差异。此外,预后模型使用了不同的时间点和大量变量组合来确定不同的临界值。尽管有效的预后模型在AHF人群中的应用前景广阔,但应为具有统一特征的AHF预后模型的推导和验证设定精确的方法学方法,以在临床实践中建立有效的性能。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验